Last Price
11.31
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Market Cap
0
Shares Outstanding
0
Avg Volume
0
Avg Price (50 Days)
0.00
Avg Price (200 Days)
0.00
PE Ratio
0.00
EPS
0.00
Earnings Announcement
Previous Close
0.00
Open
0.00
Day's Range
0.0 - 0.0
Year Range
0.0 - 0.0
Trading Volume
0
1 Day Change
5 Day Change
1 Month Change
3 Month Change
6 Month Change
Ytd Change
1 Year Change
3 Year Change
5 Year Change
10 Year Change
Max Change
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Heavenly PUNTER Lynas Boleh
Potential 20 baggers
2019-06-11 14:49